Abstract
Introduction The widespread deposition of amyloid beta (Aβ) plaques in late-stage Alzheimer’s disease (AD) is well defined and confirmed by in vivo positron emission tomography (PET). However, there are discrepancies between which regions contribute to the earliest topographical Aβ deposition within the neocortex.
Methods This study investigated Aβ signals in the peri-threshold SUVr range using Pittsburgh compound B (PiB) PET in a population-based study cross-sectionally and longitudinally. PiB-PET scans from 1,088 participants were assessed to determine the early patterns of PiB loading in the neocortex.
Results Early-stage Aβ loading is seen first in the temporal, cingulate, and occipital regions. Regional early deposition patterns are similar in both Apolipoprotein ε4 (APOE) carriers and non-carriers. Hierarchical clustering analysis shows groups with different patterns of early amyloid deposition.
Discussion These finding of initial Aβ deposition patterns may be of significance for diagnostics and understanding the development of different AD phenotypes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by National Institutes of Health grant R01 AG073282 (V.L.), National Institutes of Health grant P30 AG62677-2 (D.J.), National Institutes of Health grant R01 AG011378 (C.J.), National Institutes of Health grant R01 AG041851 (C.J.), National Institutes of Health grant P50 AG016574 (R.P.), National Institutes of Health grant U01 AG06786 (R.P.), Robert Wood Johnson Foundation, The Elsie and Marvin Dekelboum Family Foundation, The Edson Family Foundation, The Liston Family Foundation The Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, The GHR Foundation, Foundation Dr. Corinne Schuler (Geneva, Switzerland), Race Against Dementia, and the Mayo Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Participants provided written consent with approval of Mayo Clinic and Olmsted Medical Center Institutional Review Boards.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Research in context
1. Systematic review: Authors reviewed current literature using PubMed and Google Scholar. These searches found several articles linked to the topographical deposition of Aβ and PiB-PET imaging of the brain in various statescognitively unimpaired to those with Alzheimer’s disease.
2. Interpretation: Regions of deposition stated within mirror some findings of past studies analyzing early deposition patterns and also reside in areas with high functional and structural connectivity, supporting the theory that amyloid deposits in these high traffic areas.
3. Future Directions: This article serves as an important step to generalizing findings about amyloid load as our population-based study provides generalizable data. Future reports should aim to further understand these patterns using longitudinal data from AD patients, to confirm early deposition patterns more confidently for those with AD.
Data Availability
Data may be available from the authors upon reasonable request and with permission.
